Background
==========

Hepatocellular carcinoma (HCC) is the fifth most common cause of cancer, causing about 700 000 deaths worldwide per year \[[@b1-medscimonit-20-247]--[@b3-medscimonit-20-247]\]. Despite great progress in understanding the origin, development, and treatment of HCC in recent decades, the detailed molecular mechanisms have not been well characterized \[[@b2-medscimonit-20-247],[@b4-medscimonit-20-247]--[@b9-medscimonit-20-247]\]. Identification of novel molecular biomarkers of HCC is crucial to the treatment and cure of this disease \[[@b6-medscimonit-20-247]\]. Recently, mutations in the isocitrate dehydrogenase 1 (*IDH1*) gene, which encodes the enzyme to catalyze the oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG), were identified in a variety of tumor types ([Table 1](#t1-medscimonit-20-247){ref-type="table"}). Almost all of the mutations in the *IDH1* gene were heterozygous and affected the 132nd residue (IDH1 p.R132) \[[@b10-medscimonit-20-247],[@b11-medscimonit-20-247]\]. Additionally, mutations in the homologous residues p.R172 and p.R140 in the IDH2 were also frequently observed in many types of human cancers \[[@b11-medscimonit-20-247]--[@b13-medscimonit-20-247]\]. IDH mutants acquired neomorphic enzymatic activity to catalyze α-KG into 2-hydroxyglutarate (2-HG), which resulted in the accumulation of 2-HG. To date, all the detected samples with IDH1 (p.R132) and IDH2 (p.R140 and p.R172) mutations invariably have shown significant accumulation of 2-HG \[[@b14-medscimonit-20-247]--[@b18-medscimonit-20-247]\]. Further studies showed that 2-HG competitively inhibited multiple α-KG-dependent enzymes, including histone demethylases, prolyl hydroxylases (PHD) and members of the ten-eleven translocation (TET) family of proteins \[[@b19-medscimonit-20-247]--[@b22-medscimonit-20-247]\].

Based on observations that IDH1 mutations were presented in a variety of tumors ([Table 1](#t1-medscimonit-20-247){ref-type="table"}) and IDH1 activity was coordinately regulated with the cholesterol and fatty acid biosynthetic pathways in hepatic cells \[[@b23-medscimonit-20-247]\], we hypothesized that IDH1 mutations might play an active role in HCC. Previous studies failed to detect any IDH1 p.R132 mutations in patients with HCC \[[@b24-medscimonit-20-247]--[@b26-medscimonit-20-247]\], but this may be due to the limited number of patients analyzed.

In this study, we aimed to characterize the possible role of IDH1 p.R132 mutations in the carcinogenesis of HCC. We first collected cancerous tissues from 87 Chinese patients with primary HCC and screened for the presence of IDH1 p.R132 mutations. We then overexpressed IDH1 p.R132 mutants in HepG2 cells and quantified the expression levels of multiple α-KG-dependent enzymes and associated genes.

Material and Methods
====================

Patients and mutational analysis
--------------------------------

Tissue samples from a total of 87 Han Chinese patients with primary HCC were collected at the YouAn Hospital of Capital Medical University. Among them, 27 patients had both primary cancerous and adjacent normal liver tissues and 60 patients only had cancerous tissues. The criteria for pathological diagnosis of HCC were based on the results after surgical resection by 2 independent pathologists. The study conformed to the tenets of the Declaration of Helsinki and written informed consent was obtained from all patients prior to participation in the study. The institutional review boards of the Kunming Institute of Zoology and Capital Medical University approved this study.

Genomic DNA was isolated from paraffin-embedded tumor tissues (N=87) and normal tissues (N=27) that were dissected from the hematoxylin-eosin stained slides using FFPE DNA kits (Omega Bio-tek, Inc. USA). We amplified a short fragment with a size of 269 bp using primer pair hIDH1f (5′-TGCTGCAGAAGCTATAAAGAAG-3′) \[[@b27-medscimonit-20-247]\]/hIDH1r (5′-GCAAAATCACATTATTGCCAAC-3′). PCR products were sequenced using the amplification primers and the Big Dye Terminator v. 3.1 Cycle Sequencing Kit (Applied Biosystems, CA, USA) on an ABI Prism 3730 DNA sequencer (Applied Biosystems, CA, USA) according to the manufacturer's manual.

Plasmid construction, cell culture, and transfection
----------------------------------------------------

The wild-type human IDH1 and p.R132H mutant (c.395G\>A) constructs were obtained as generous gifts from Drs Kun-Liang Guan and Yue Xiong (Fudan University, China). We generated two IDH1 p.R132 mutants (p.R132C, c.394C\>T and p.R132G, c.394C\>G) based on the wild-type IDH1 by using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA). All constructs were verified by sequencing.

HepG2 cells were bought from the Kunming Cell Bank, Kunming Institute of Zoology, which was initially introduced from ATCC. Cells were cultured in DMEM medium with 10% fetal bovine serum (Gibco-BRL, Gaithersburg, MD) at 37°C in 5% CO~2~. In brief, cells (5×10^4^ per well) were seeded in 12-well plates and grown to 80% confluence. HepG2 cells were transfected with pcDNA3.1 empty vector, IDH1 wild-type and p.R132 mutants (p.R132H, c.395G\>A; p.R132C, c.394C\>T and p.R132G, c.394C\>G), respectively. For each well, a mixture of 1 μg plasmid DNA and 2.5 μL FuGENE^®^ HD Transfection Reagent (Roche, Indianapolis, IN, USA) in a volume of 50 μL was incubated at room temperature for 20 min. Meanwhile, culture medium from cells was removed and washed once with Opti-MEM medium (Gibco-BRL, Gaithersburg, MD). DNA/FuGENE HD complex was added to each well, together with an additional 450 μL Opti-MEM. After incubation for 6 h, 1 mL of growth medium was added to each well. Cells were then incubated at 37°C for another 42 h until performance of the protein and gene expression assay. All cells were harvested 48 h later after transient transfection. To mimic hypoxia, untransfected cells were washed once with phosphate-buffered saline and incubated in 200 μM CoCl~2~ (Sigma-Aldrich, USA) for 6 h before harvesting.

Quantitative real-time PCR
--------------------------

Total RNA was isolated from HepG2 cells 48 h post-transfection using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA). 1 μg total RNA was used to synthesize cDNA using M-MLV Reverse Transcriptase (Promega Corp., Madison, WI, USA) with an oligo(dT) 18 primers. Quantitative real-time PCR was performed on MyiQ2 Two-Color Real-Time PCR Detection system (BioRad Laboratories, Hercules, CA, USA) with SYBR^®^ Premix Ex Taq™ II kit (TaKaRa Biotechnology Co., Ltd. Dalian, China) according to the manufacturer's instructions. The primers for *GLUT1*, *VEGF, HOXA2*, *HOXA4*, *HOXA5*, *HOXA6,* and *HOXA7* genes are shown in [Table 2](#t2-medscimonit-20-247){ref-type="table"}. The mRNA expression of human glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*) gene was used as an internal control for normalization.

Western blotting
----------------

Cells were collected at 48 h post-transfection and proteins were extracted by cell lysis buffer (Beyotime Institute of Biotechnology, Jiangsu, China). Protein samples were separated on 8--12% SDS-PAGE gel and transferred onto polyvinylidene fluoride (PVDF) membranes (Roche Diagnostics, USA) using standard procedures. The membranes were blocked at room temperature for 2 h with 5% nonfat dry milk. Membranes were incubated with primary antibody against FLAG (1:2000, EneGene Biotech Co. Ltd, China), HIF-1α (1:1000, Novus Biologicals, Kittketon, Co, USA), H3K4me3 (1:5000, Abcam, UK), H3K79me2 (1:3000, Active Motif, Inc. Japan), GAPDH (1:5000, EneGene Biotech Co. Ltd, China), β-actin (1:100000, EnoGene Biotech Co. Ltd, China), and tubulin (1:10000, EnoGene Biotech Co. Ltd, China) overnight at 4°C. Membranes were washed 3 times for 10 min each and incubated for 1 h at room temperature with horseradish peroxidase-conjugated anti-mouse or anti-rabbit secondary antibody (1:10000, KPL, Gaithersburg, MD, USA). The proteins were detected using enhanced chemiluminescence (ECL) reagents (Millipore, Billerica, MA, USA).

Statistical analysis
--------------------

For measurement of the expression levels of multiple α-KG-dependent enzymes and associated genes in HepG2 cells overexpressing IDH1 p.R132 mutants, each assay was independently performed at least 3 times to validate the consistency of the results. Data was presented as mean ±SD of 3 independent tests. Statistical analysis was performed with GraphPad software (GraphPad Software, La Jolla, CA, USA) with unpaired Student's t-test.

Results
=======

Absence of IDH1 p.R132 mutations in 87 HCC patients
---------------------------------------------------

We sequenced the region covering IDH1 p.R132 mutations in a total of 87 Chinese patients with HCC. Among them, 27 patients were analyzed for both cancerous tissues and paired normal tissues. None of the analyzed samples were found to harbor any IDH1 p.R132 mutations ([Figure 1](#f1-medscimonit-20-247){ref-type="fig"}). This observation is consistent with previous reports for patients from Korea and America \[[@b24-medscimonit-20-247]--[@b26-medscimonit-20-247]\].

Overexpression of IDH1 p.R132 mutants in HepG2 cells did not influence the expression of α-KG-dependent enzymes and downstream target genes
-------------------------------------------------------------------------------------------------------------------------------------------

Previous studies have characterized the potential mechanism of the IDH1 mutations in carcinogenesis \[[@b14-medscimonit-20-247],[@b20-medscimonit-20-247],[@b28-medscimonit-20-247]\] ([Figure 2](#f2-medscimonit-20-247){ref-type="fig"}). To further explore whether the IDH1 p.R132 mutations (c.395G\>A, c.394C\>T and c.394C\>G) would have an effect on the development of HCC, we first determined the level of HIF-1α protein and the mRNA expression levels of *GLUT1* and *VEGF* genes, which were indirectly regulated by PHD and associated with the activation of the HIF-1α signaling pathway \[[@b28-medscimonit-20-247]\]. Compared with cells expressing IDH1 wild-type, all 3 mutants did not significantly increase protein expression levels of HIF-1α in HepG2 cells ([Figure 3A](#f3-medscimonit-20-247){ref-type="fig"}). The real-time PCR results showed that overexpression of all 3 mutants did not significantly increase mRNA expression levels of *GLUT1* and *VEGF* genes in HepG2 cells ([Figure 3B](#f3-medscimonit-20-247){ref-type="fig"}). These negative results led us to speculate whether IDH1 mutations affect the production of 2-HG in HepG2 cells. Recent reports showed that elevated 2-HG increased histone methylations and altered the expression level of *HOXA* genes family in cells that were overexpressed IDH1 p.R132H mutant \[[@b20-medscimonit-20-247],[@b21-medscimonit-20-247]\]. We measured the H3K4me3 and H3K79me2 proteins and the *HOXA* mRNA level in HepG2 cells expressing IDH1 p.R132 mutants, but discerned no effect of any of the 3 mutations on change of the histone methylation protein level in HepG2 cells ([Figure 3](#f3-medscimonit-20-247){ref-type="fig"}).

Discussion
==========

Since the initial observation that *IDH1* gene mutations presented in glioblastoma multiforme \[[@b10-medscimonit-20-247]\], a series of studies have been performed to detect the presence of such mutations in a variety of tumors. These prior studies showed that almost all mutations in the *IDH1* gene were IDH1 p.R132, and none of the analyzed samples with HCC harbored IDH1 p.R132 mutations ([Table 1](#t1-medscimonit-20-247){ref-type="table"}). Additionally, subsequent functional assays found that the mutations in the *IDH1* gene might contribute to carcinogenesis via accumulation of 2-HG, which could be substantially attributed to the inhibition of α-KG-dependent enzymes.

In this study, we first detected IDH1 p.R132 mutations in Han Chinese patients with HCC, to test whether IDH1 mutations were presented in HCC. Our screening for cancerous tissues or paired cancerous and normal tissues from 87 patients showed no *IDH1* p.R132 mutations ([Figure 1](#f1-medscimonit-20-247){ref-type="fig"}). The absence of the *IDH1* p.R132 mutations in HCC analyzed here and elsewhere indicate that changes at this position may not be actively involved in the pathogenesis of HCC \[[@b24-medscimonit-20-247]--[@b26-medscimonit-20-247]\]. Recent studies have found recurrent IDH1 mutations in cholangiocarcinoma \[[@b26-medscimonit-20-247],[@b29-medscimonit-20-247],[@b30-medscimonit-20-247]\]. However, due to the relatively limited sample size analyzed in this and prior studies \[[@b24-medscimonit-20-247]--[@b26-medscimonit-20-247]\], it is still hard to draw a definite conclusion that *IDH1* p.R132 mutations are not presented in HCC. Moreover, recent studies showed that all detected samples with IDH1 p.R132 mutations presented the accumulation of 2-HG \[[@b14-medscimonit-20-247]--[@b18-medscimonit-20-247]\]. Simultaneously, mutant IDH1 might also activate histone methylations and PHD downstream target genes, including *HOXA* genes, *GLUT1,* and *VEGF* genes \[[@b20-medscimonit-20-247],[@b28-medscimonit-20-247]\]. Based on these observations ([Figure 2](#f2-medscimonit-20-247){ref-type="fig"}), we tested whether overexpression of IDH1 p.R132 mutants would lead to upregulation of those genes associated with the activation of the 2-HG signaling pathway, to further determine if IDH1 mutations are involved in the development of HCC. However, our measurement revealed no essential change in the expression levels of HIF-1α target genes or histone methylation marker genes in HepG2 cells with overexpression of IDH1 p.R132 mutants and wild-type ([Figure 3](#f3-medscimonit-20-247){ref-type="fig"}). A limitation of this cellular observation is that the changes in histone methylation protein and mRNA expression levels of *VEGF*, *GLUT1* and *HOXA* were, at best, secondary effects of mutant IDH1 activity. An evaluation of mutant IDH1 activity should have included the measurement of 2-hydroxyglutarate levels in cells and media to discern the direct downstream effect. Although we did not quantify the level of 2-HG in transfected cells and culture medium due to lack of required equipment, we think that it might not be altered, because no 2-HG induced genes were changed. Taken together, our results indicate that IDH1 p.R132 mutations may not play an active role in HCC. Another limitation of the current cellular assay is that we only analyzed HepG2 cells. It may be more proper to work on human primary hepatocytes \[[@b31-medscimonit-20-247],[@b32-medscimonit-20-247]\].

One equally important issue regarding the role of the *IDH1* gene in the development of solid tumors is whether the haplotype and/or rare variant(s) of this gene are a risk factor for cancer susceptibility and development. According to the latest released HapMap phase 3 data (*<http://hapmap.ncbi.nlm.nih.gov/>*), there are 5 haplotypes of the *IDH1* gene that were characterized by 5 SNPs (rs6730955, rs16840798, rs6435435, rs3769521, and rs1437410) in all 255 East Asian samples or samples of East Asian origin. It would be rewarding to genotype all these SNPs in patient samples and to identify the potential association between the onset of cancer and the allele/genotype/haplotype of the *IDH1* gene. Detecting rare variant(s) requires extremely larger sample size and deep sequencing of the genomic region covering the *IDH1* gene. Unfortunately, we used up the tiny amount of DNA from the hematoxylin/eosin stained slides and could not test the above speculation in this study. In addition, accumulating evidence has shown that IDH2 mutations (p.R140 and p.R172) exhibit similar tumor-promoting roles as IDH1 p.R132 mutations \[[@b15-medscimonit-20-247],[@b18-medscimonit-20-247],[@b29-medscimonit-20-247]\]. We did not test whether these IDH2 hotspot mutations were involved in our samples due to the lack of sufficient DNA. Further research should be carried out to clarify this issue.

Conclusions
===========

Taken together, we detected no IDH1 p.R132 mutation in 87 Chinese HCC samples. IDH1 p.R132 mutants might not lead to alteration of expression of these genes involved in the previously well characterized cellular pathways in HepG2 cells. Our results suggest that IDH1 p.R132 mutations are not be actively involved in HCC. Further studies should be carried out to characterize the exact role of the *IDH1* and *IDH2* genes in HCC and to validate our negative observations.
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![Representative sequencing electrophoregrams of the wide-type *IDH1* codon 132 in the paired cancerous and normal tissues from a Chinese patient with primary hepatocellular carcinoma.](medscimonit-20-247-g001){#f1-medscimonit-20-247}

![Summarization of the role of IDH1 mutants and 2-HG signaling in cellular pathway. IDH1 mutants inhibit its normal catalytic activity and acquire the ability to convert α-ketoglutarate (α-KG) to 2-hydroxyglutarate (2-HG). 2-HG competitively inhibited multiple α-KG-dependent enzymes, including prolylhydroxylases (PHD) and histone demethylases.](medscimonit-20-247-g002){#f2-medscimonit-20-247}

![Overexpression of IDH1 p.R132 mutants in HepG2 cells had no effect on the expression levels of (**A**) HIF-1α, H3K4me3 and H3K79me2 proteins and (**B**) *GLUT1* and *VEGF* and H3K79 dimethylation association genes (*HOXA* genes). The protein expression of HIF-1α, H3K4me3 and H3K79me2 were analyzed by Western blotting with the indicated antibodies. The relative mRNA expression levels of HIF-1α target genes (GLUT1 and VEGF) and H3K79 dimethylation association genes (*HOXA* genes) were analyzed by quantitative real-time PCR. All mRNA quantifications were normalized to cells transfected with pCDNA3.1 empty vector. NC -- non-treated cells. Values are shown in Mean ±SD. Results are representative of three different experiments.](medscimonit-20-247-g003){#f3-medscimonit-20-247}

###### 

Summary of previously reported IDH1 p.R132 mutations in human diseases.

  Diseases                            Total number of samples[\*](#tfn2-medscimonit-20-247){ref-type="table-fn"}   Samples with mutation   Mutation frequency   Frequency range   Number of IDH1-related reports [\*\*](#tfn3-medscimonit-20-247){ref-type="table-fn"}
  ----------------------------------- ---------------------------------------------------------------------------- ----------------------- -------------------- ----------------- --------------------------------------------------------------------------------------
  **Brain tumors**                                                                                                                                                                
   Gliomas                            18297                                                                        6432                    35.2%                0.0--100.0%       168
   Non-glioma brain tumors            2232                                                                         675                     30.2%                0.0--100.0%       30
  **Hematological malignancies**                                                                                                                                                  
   AML                                15509                                                                        1053                    6.8%                 0.0--25.0%        68
   MDS/MPD/MPN                        4376                                                                         82                      1.9%                 0.0--18.8%        28
   NHL                                640                                                                          1                       0.2%                 0.0--0.8%         4
   ALL                                567                                                                          3                       0.5%                 0.0--3.2%         6
   CML                                479                                                                          0                       0.0%                 0.0%              7
   HL                                 122                                                                          0                       0.0%                 0.0%              3
   MM                                 92                                                                           0                       0.0%                 0.0%              2
   CLL                                18                                                                           0                       0.0%                 0.0%              2
   AMML                               3                                                                            0                       0.0%                 0.0%              1
  **Others**                                                                                                                                                                      
   Mesenchymal tumour                 1200                                                                         74                      6.2%                 6.2%              1
   Colorectal cancer                  926                                                                          3                       0.3%                 0.0--2.9%         8
   Breast cancer                      603                                                                          1                       0.2%                 0.0--100.0%       6
   Lung cancer                        517                                                                          0                       0.0%                 0.0%              6
   Sarcoma                            529                                                                          1                       0.2%                 0.0--100.0%       3
   Pheochromocytoma                   314                                                                          0                       0.0%                 0.0%              2
   Prostate cancer                    387                                                                          7                       1.8%                 0.0--2.7%         6
   Pancreatic cancer                  293                                                                          0                       0.0%                 0.0%              4
   Thyroid Cancer                     504                                                                          19                      3.8%                 0.0--15.7%        6
   Cholangiocarcinoma                 482                                                                          45                      9.3%                 7.1--14.9%        3
   GIST                               180                                                                          0                       0.0%                 0.0%              2
   Enchondroma and related diseases   278                                                                          103                     37.1%                1.0--90.0%        4
   Gastric cancer                     190                                                                          0                       0.0%                 0.0%              3
   Ovarian cancer                     176                                                                          0                       0.0%                 0.0%              4
   Hepatocellular carcinoma           159                                                                          0                       0.0%                 0.0%              3
   Paraganglioma                      155                                                                          1                       0.6%                 0.0--0.8%         2
   Renal cancer                       161                                                                          0                       0.0%                 0.0%              5
   Melanoma                           173                                                                          3                       1.7%                 0.0--5.1%         4
   Squamous cell carcinoma (oral)     90                                                                           0                       0.0%                 0.0%              1
   Biliary tract cancer               87                                                                           9                       10.3%                10.3%             1
   Esophageus cancer                  73                                                                           0                       0.0%                 0.0%              2
   Bladder cancer                     38                                                                           0                       0.0%                 0.0%              1
   Fibrous histiocytoma               36                                                                           0                       0.0%                 0.0%              1
   Urothelial carcinoma               28                                                                           0                       0.0%                 0.0%              1
   Gallbladder cancer                 25                                                                           0                       0.0%                 0.0%              3
   Squamous cell carcinoma (skin)     19                                                                           0                       0.0%                 0.0%              1
   Mesothelioma                       18                                                                           0                       0.0%                 0.0%              3
   Endometrial                        18                                                                           0                       0.0%                 0.0%              1
   Cervical cancer                    11                                                                           0                       0.0%                 0.0%              2
   NPC                                7                                                                            0                       0.0%                 0.0%              1
   HNSCC                              1                                                                            0                       0.0%                 0.0%              1

AML -- acute myeloid leukemia; MDS/MPD/MPN -- myelodysplastic/myeloproliferative diseases/neoplasms; NHL -- non-Hodgkin lymphoma; ALL -- acute lymphocytic leukemia; CML -- chronic myeloid leukemia; HL -- Hodgkin lymphoma; MM -- multiple myeloma; CLL -- chronic lymphocytic leukemia; AMLL -- acute mixed lineage leukemia; GIST -- gastrointestinal stromal tumor; NPC -- nasopharyngeal carcinoma; HNSCC -- head and neck squamous cell cancer.

The last PubMed search was performed on March 8, 2013.

Papers with redundant data were not included in this table. Due to the limit of reference list for the paper, we have to present the entire list of all 293 references at *<http://www.mitotool.org/lab/pdf/IDH1_Table_1.pdf>*.

###### 

Primers used for quantitative real-time PCR.

  Primer name                                                    Sequence (5′-3′)         Product length (bp)   GenBank accession number   Annealing temperature (°C)
  -------------------------------------------------------------- ------------------------ --------------------- -------------------------- ----------------------------
  GAPDH_F[\*](#tfn4-medscimonit-20-247){ref-type="table-fn"}     CAACTACATGGTTTACATGTTC   181                   --                         55
  GAPDH_R[\*](#tfn4-medscimonit-20-247){ref-type="table-fn"}     GCCAGTGGACTCCACGAC                                                        
                                                                                                                                           
  GLUT1_F[\*\*](#tfn5-medscimonit-20-247){ref-type="table-fn"}   GATTGGCTCCTTCTCTGTGG     129                   --                         55
  GLUT1_R[\*\*](#tfn5-medscimonit-20-247){ref-type="table-fn"}   TCAAAGGACTTGCCCAGTTT                                                      
                                                                                                                                           
  VEGF_F[\*\*](#tfn5-medscimonit-20-247){ref-type="table-fn"}    AGGAGGAGGGCAGAATCATCA    74                    --                         55
  VEGF_R[\*\*](#tfn5-medscimonit-20-247){ref-type="table-fn"}    CTCGATTGGATGGCAGTAGCT                                                     
                                                                                                                                           
  HOXA2_F                                                        AACCTAACTCAACAACCC       116                   NM_006735.3                55
  HOXA2_R                                                        ATGCATCCCAATGTAATA                                                        
                                                                                                                                           
  HOXA4_F                                                        CTTGATGGTAGGTGTGAC       80                    NM_002141.4                55
  HOXA4_R                                                        AAGGGGACAACAGTATCT                                                        
                                                                                                                                           
  HOXA5_F                                                        TTTAGTGCCAATGTTGTG       88                    NM_019102.2                55
  HOXA5_R                                                        TAACAGCTTGGAGCTATT                                                        
                                                                                                                                           
  HOXA6_F                                                        AGGCGGGCGAGTAGATGC       100                   NM_024014.2                65
  HOXA6_R                                                        GCGGGGAGAAAAGTTGGG                                                        
                                                                                                                                           
  HOXA7_F                                                        TGGGGTGACTTTGTAGCA       89                    NM_006896.3                60
  HOXA7_R                                                        AGGAGATGAAGGGCATTG                                                        

These primers are taken from Zhou et al. \[[@b33-medscimonit-20-247]\];

These primers are taken from Zhao et al. \[[@b28-medscimonit-20-247]\].
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